Table 4.

Comparisons of the Differences in Blood Glucose Levels at the Time of Transition and the Length of Hospital Stay by Group

Variable		Difference in glucose levels before PSM (n=165)		Difference in glucose levels after PSM (n=108)		Length of hospital stay (n=144)
		Β±SE	P value	Β±SE	P value	Β±SE	P value
Univariable
	Groupa	–79.92±15.34	<0.001b	–84.83±18.76	<0.001b	–1.13±0.56	0.046b
Multivariable
	Groupa	–84.61±22.88	<0.001b	–84.59±25.76	0.001b	–1.20±0.53	0.027b
	Age, yr	–0.29±0.49	0.562	–0.86±0.62	0.169	–0.00±0.02	0.837
	BMI, kg/m2	3.19±2.02	0.117	1.54±2.37	0.519	-	-
	Classification (DKA)c	–27.80±22.91	0.227	–35.76±27.97	0.204	0.52±0.78	0.505
	Classification (HHS)c	–27.09±23.40	0.249	–33.38±28.48	0.244	1.64±0.81	0.043b
	Classification (HHS with ketoacidosis)c	–14.423±22.26	0.518	–21.64±27.85	0.439	0.38±0.75	0.613
	Dose of basal insulin, U	–0.66±1.53	0.669	0.38±1.71	0.825	-	-
	Duration of CIII, hr	–0.27±0.41	0.511	–0.42±0.44	0.353	0.02±0.01	0.056
	Glucose level immediately before CIII discontinuation, mg/dL	–0.90±0.19	<0.001b	–0.96±0.23	<0.001b	-	-
	Duration of DM, yr	0.63±0.86	0.467	1.85±1.07	0.085	–0.03±0.03	0.390
	Precipitating factor	–27.92±17.33	0.109	–22.10±20.55	0.285	2.11±0.63	0.001b
	OHA (metformin)	3.79±22.97	0.869	–0.95±27.07	0.972	-	-
	OHA (sulfonylurea)	9.41±23.13	0.685	14.73±28.66	0.609	-	-
	OHA (DPP4 inhibitor)	–1.55±23.70	0.948	–24.65±28.47	0.389	-	-
	OHA (SGLT2 inhibitor)	3.71±40.16	0.927	21.15±45.66	0.645	-	-

B, β coefficient; SE, standard error; PSM, propensity score matching; BMI, body mass index; DKA, diabetic ketoacidosis; HHS, hyperosmolar hyperglycemic state; CIII, continuous intravenous insulin infusion; DM, diabetes mellitus; OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium/glucose cotransporter 2.

^aEarly vs. delayed basal insulin group;

^bValues are statistically significant (P<0.05) by linear regression analyses;

^cData are compared to the category of severe hyperglycemia that did not satisfy the criteria for either DKA or HHS.